This study is for adults with a type of advanced cancer called neuroendocrine cancer (NEC). These cancers must have a marker called DLL3. The study is testing a new medicine called BI 764532, which is given with chemotherapy. The study has two parts. In Part A, researchers find the highest dose of BI 764532 that people can handle with chemotherapy. In Part B, they see how well people tolerate BI 764532 with different chemotherapies.
Participants receive BI 764532 and chemotherapy through an infusion into a vein. If they benefit and tolerate the treatment, they may continue for up to 3 years. Participants visit doctors regularly to check their health and monitor any side effects. Doctors also measure the size of the tumor often.
- Study lasts up to 3 years with regular doctor visits.
- Participants receive medicine through a vein.
- Only adults with specific cancer markers can join.
How understandable was the trial content above?
Hard to understand
Easy to understand